Q1 Earnings Forecast for Cingulate Issued By Roth Capital

Cingulate Inc. (NASDAQ:CING) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for Cingulate in a report issued on Monday, March 31st. Roth Capital analyst B. Pachaiyappan anticipates that the company will post earnings per share of ($0.48) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.76) EPS.

Several other equities analysts have also issued reports on CING. Roth Mkm started coverage on shares of Cingulate in a report on Friday, January 10th. They set a “buy” rating and a $12.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Cingulate in a report on Thursday, March 6th.

Cingulate Price Performance

Shares of Cingulate stock opened at $4.16 on Tuesday. Cingulate has a 1 year low of $1.80 and a 1 year high of $20.83. The company has a 50-day moving average of $4.24 and a 200 day moving average of $4.43. The firm has a market cap of $13.36 million, a price-to-earnings ratio of -0.28 and a beta of -0.83.

Institutional Investors Weigh In On Cingulate

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC purchased a new stake in Cingulate during the 4th quarter valued at $135,000. Commonwealth Equity Services LLC boosted its position in shares of Cingulate by 281.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock valued at $212,000 after buying an additional 31,746 shares during the last quarter. AlphaMark Advisors LLC increased its holdings in Cingulate by 50,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after buying an additional 5,000 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Cingulate in the 3rd quarter worth about $106,000. Institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.